Compare SIEB & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SIEB | IXHL |
|---|---|---|
| Founded | 1886 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 134.7M |
| IPO Year | N/A | N/A |
| Metric | SIEB | IXHL |
|---|---|---|
| Price | $3.02 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.3K | ★ 7.5M |
| Earning Date | 11-12-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $90,289,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.05 | ★ N/A |
| Revenue Growth | ★ 8.32 | N/A |
| 52 Week Low | $2.08 | $0.08 |
| 52 Week High | $5.77 | $2.25 |
| Indicator | SIEB | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 40.72 |
| Support Level | $2.92 | $0.34 |
| Resistance Level | $3.24 | $0.42 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 8.70 | 21.16 |
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.